Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters










Database
Language
Publication year range
1.
J Cardiovasc Pharmacol Ther ; 15(2): 196-202, 2010 Jun.
Article in English | MEDLINE | ID: mdl-20332533

ABSTRACT

Cholesteryl ester transfer protein (CETP) plays a key role in high-density lipoprotein (HDL) cholesterol metabolism, but normal mice are deficient in CETP. In this study, transgenic mice expressing both human apolipoprotein B 100 (ApoB-100) and human CETP (hApoB100/hCETP) were used to characterize the effects of CETP inhibition and peroxisome proliferator-activated receptor alpha (PPARalpha) agonism on lipid profiles. Torcetrapib (3, 10, and 30 mg/kg), a CETP inhibitor, fenofibrate (30 mg/kg), a weak PPARalpha agonist, and GW590735 (3 and 10 mg/kg), a potent and selective PPARalpha agonist were given orally for 14 days to hApoB100/hCETP mice and lipid profiles were assessed. The average percentages of HDL, low-density lipoprotein (LDL), and very-low-density lipoprotein (VLDL) cholesterol fractions in hApoB100/hCETP mice were 34.8%, 61.6%, and 3.6%, respectively, which is similar to those of normolipidemic humans. Both torcetrapib and fenofibrate significantly increased HDL cholesterol and reduced LDL cholesterol, and there was a tendency for torcetrapib to reduce VLDL cholesterol and triglycerides. GW590735 significantly increased HDL cholesterol, decreased LDL and VLDL cholesterol, and significantly reduced triglycerides. Maximal increases in HDL cholesterol were 37%, 53%, and 84% with fenofibrate, torcetrapib, and GW590735, respectively. These results, in mice that exhibit a more human-like lipid profile, demonstrate an improved lipid profile with torcetrapib, fenofibrate, and GW590735, and support the use of selective PPARalpha agonism for the treatment of lipid disorders. In addition, these data demonstrate the use of hApoB100/hCETP transgenic mice to identify, characterize, and screen compounds that increase HDL cholesterol.


Subject(s)
Anticholesteremic Agents/pharmacology , Apolipoprotein B-100/genetics , Cholesterol Ester Transfer Proteins/antagonists & inhibitors , Cholesterol, HDL/blood , Cholesterol, LDL/blood , PPAR alpha/agonists , Animals , Cholesterol Ester Transfer Proteins/genetics , Cholesterol, VLDL/blood , Dose-Response Relationship, Drug , Fenofibrate/pharmacology , Humans , Mice , Mice, Transgenic , Propionates/pharmacology , Quinolines/administration & dosage , Quinolines/pharmacology , Thiazoles/pharmacology
2.
Pharmacology ; 81(1): 1-10, 2008.
Article in English | MEDLINE | ID: mdl-17726342

ABSTRACT

BACKGROUND/AIMS: Isradipine, a calcium channel blocker, provides consistent protection of the brain from injury and reduces neurological deficits produced by ischemic stroke in hypertensive rats. In these experiments, isradipine was utilized to cross-validate both the serial MRI measurement of brain infarctions with histology measurements and to validate a series of simple neurological deficit tests in order to establish a more rapid, higher throughput approach to screening compounds for utility in stroke. METHODS: Spontaneously hypertensive rats were treated with vehicle, or 2.5 or 5.0 mg/kg isradipine and middle cerebral artery occlusion. T(2)-weighted MRI image analysis was compared to standard triphenyltetrazolium chloride-stained histological image analysis of brain sections to quantify isradipine neuroprotection 1, 3, and 30 days after middle cerebral artery occlusion (MCAO; stroke). In addition, serial evaluation (i.e. 1, 2, 5, 12, 20 and 30 days after MCAO) of four simple neurobehavioral tests were completed for each animal. Tests included assessment of hindlimb and forelimb function, and balance beam and proprioception performance. RESULTS: At 1, 3 and 30 days there was a significant positive correlation of the percent hemispheric infarct for T(2)-weighted MRI and histology (p < 0.05). Practically identical isradipine dose-response neuroprotection curves were observed for both measurement procedures. Isradipine produced a dose-related reduction in all neurological deficits scored by the four neurological deficit tests (p < 0.05). In addition, a significant time-related recovery from neurological deficits in vehicle-treated rats was observed (p < 0.05). The four different neurological deficit tests did provide unique time-related profiles of neurological recovery. CONCLUSIONS: The present study validates the use of serial MRI in experimental stroke and establishes several simple neurological tests that can be used to measure neurological/behavioral deficits associated with brain injury and brain recovery of function over time. Under these conditions, T(2)-weighted MRI and neurological testing required only about 10 min each per animal, thus providing rapid data collection and analysis and requiring reduced scientific personnel.


Subject(s)
Behavior, Animal/drug effects , Brain Infarction , Calcium Channel Blockers/therapeutic use , Isradipine/therapeutic use , Magnetic Resonance Imaging , Animals , Brain Infarction/drug therapy , Brain Infarction/pathology , Brain Infarction/physiopathology , Calcium Channel Blockers/administration & dosage , Disease Models, Animal , Isradipine/administration & dosage , Male , Neuropsychological Tests , Predictive Value of Tests , Rats , Rats, Inbred SHR , Treatment Outcome
3.
Pharmacology ; 81(1): 11-7, 2008.
Article in English | MEDLINE | ID: mdl-17726343

ABSTRACT

BACKGROUND/AIMS: Phosphodiesterase type 4 (PDE4) has been previously shown to regulate colonic contractile activity in vitro. In this study, the effects of PDE4 inhibition were assessed in a model of stress-induced defecation previously demonstrated to be due to increased colonic transit/evacuation. METHODS: Rats were individually placed in a mild restraint cage and placed into a 12 degrees C environment (cold-restraint stress) for 60 min. Mice received restraint (only) stress at room temperature for 30 min. Loperamide (positive control compound) or two different PDE4 inhibitors (rolipram and roflumilast) were administered orally at several doses to the rodents 1 h before stress began. Vehicle alone was administered for comparison. The number of fecal pellets expelled during stress (fecal pellet output), total fecal pellet wet weight and total fecal water content were measured. RESULTS: Loperamide produced a dose-related decrease (ID(50)s in mg/kg) in fecal pellet output (rat = 7.4, mouse = 0.7) and significantly decreased fecal wet weight (72.9%) and decreased fecal percent water content (9.4%). The two PDE4 inhibitors produced a similar dose-related inhibition of fecal pellet output. Rolipram exhibited ID(50)s in rat and mouse of 14.1 and 27.1, respectively. Rolipram significantly decreased fecal wet weight (58.8%) but increased fecal percent water content (15.0%). For roflumilast, ID(50)s were 24.2 mg/kg and 12.4 in the rat and mouse, respectively. Although roflumilast also significantly (p < 0.05) decreased fecal wet weight (47.2%), it did not significantly increase fecal percent water content. CONCLUSIONS: These data indicate that PDE4 inhibition is effective in reducing rodent stress-induced defecation, provides the first functional data on a potential role for PDE4 activity in the colonic evacuation response to stress, and indicates the potential utility of PDE4 inhibitors in functional bowel disease such as irritable bowel syndrome requires further evaluation.


Subject(s)
Defecation/drug effects , Gastrointestinal Motility/drug effects , Phosphodiesterase 4 Inhibitors , Phosphodiesterase Inhibitors/therapeutic use , Stress, Psychological/physiopathology , Aminopyridines/administration & dosage , Aminopyridines/pharmacology , Aminopyridines/therapeutic use , Animals , Antidiarrheals/administration & dosage , Antidiarrheals/pharmacology , Antidiarrheals/therapeutic use , Benzamides/administration & dosage , Benzamides/pharmacology , Benzamides/therapeutic use , Cold Temperature , Cyclopropanes/administration & dosage , Cyclopropanes/pharmacology , Cyclopropanes/therapeutic use , Irritable Bowel Syndrome/etiology , Irritable Bowel Syndrome/prevention & control , Loperamide/administration & dosage , Loperamide/pharmacology , Loperamide/therapeutic use , Male , Mice , Mice, Inbred C57BL , Phosphodiesterase Inhibitors/administration & dosage , Phosphodiesterase Inhibitors/pharmacology , Rats , Rats, Sprague-Dawley , Restraint, Physical , Rolipram/administration & dosage , Rolipram/pharmacology , Rolipram/therapeutic use , Stress, Psychological/complications , Stress, Psychological/enzymology
4.
Neurosci Lett ; 339(2): 151-5, 2003 Mar 20.
Article in English | MEDLINE | ID: mdl-12614917

ABSTRACT

Ischemic preconditioning (PC) is a phenomenon whereby a brief exposure to ischemia renders a tissue more tolerant to a subsequent sustained ischemic insult. Animals of the Spontaneously Hypertensive (SHR) and the Spontaneously Hypertensive Stroke-Prone (SHR-SP) rat strains produce cerebral infarcts that are larger and more reproducible in size than infarcts of normotensive rats. This study compared the effects of PC in SHR and SHR-SP rats, under the hypothesis that PC may not be as effective in the SHR-SP, a strain genetically predisposed to stroke. There were two groups per strain, with between eight and ten animals each. The Precondition group (PC) had a 10 min occlusion of the middle cerebral artery on day -1. On the same day the Sham group (Sham) received sham surgery. On day 0, both groups underwent permanent occlusion of the middle cerebral artery. The ischemic lesion was measured on day 1 using T(2)-weighted magnetic resonance imaging. Percent hemispheric infarct was significantly reduced in SHR PC vs. SHR Sham, SHR-SP PC vs. SHR-SP Sham, and SHR PC vs. SHR-SP PC. Thus, rats of the SHR-SP strain respond to PC less markedly than SHR animals. Both models may now be used to elucidate the mechanisms underlying PC.


Subject(s)
Brain Infarction/pathology , Brain Ischemia/complications , Hypertension/genetics , Ischemic Preconditioning , Stroke/genetics , Animals , Brain Infarction/etiology , Infarction, Middle Cerebral Artery/complications , Magnetic Resonance Imaging/methods , Male , Rats , Rats, Inbred SHR , Species Specificity
5.
Proc Natl Acad Sci U S A ; 100(2): 715-20, 2003 Jan 21.
Article in English | MEDLINE | ID: mdl-12522260

ABSTRACT

Sublethal insults can induce tolerance to subsequent stressors in neurons. As cell death activators such as ROS generation and decreased ATP can initiate tolerance, we tested whether other cellular elements normally associated with neuronal injury could add to this process. In an in vivo model of ischemic tolerance, we were surprised to observe widespread caspase 3 cleavage, without cell death, in preconditioned tissue. To dissect the preconditioning pathways activating caspases, and the mechanisms by which these proteases are held in check, we developed an in vitro model of excitotoxic tolerance. In this model, antioxidants and caspase inhibitors blocked ischemia-induced protection against N-methyl-d-aspartate toxicity. Moreover, agents that blocked preconditioning also attenuated induction of HSP 70; transient overexpression of a constitutive form of this protein prevented HSP 70 up-regulation and blocked tolerance. We outline a neuroprotective pathway where events normally associated with apoptotic cell death are critical for cell survival.


Subject(s)
Caspases/physiology , Ischemic Preconditioning , Neurons/pathology , Animals , Caspase 3 , Cells, Cultured , Enzyme Activation , HSP70 Heat-Shock Proteins/biosynthesis , N-Methylaspartate/pharmacology , Potassium Channels/physiology , Proto-Oncogene Proteins c-bcl-2/biosynthesis , Rats , Reactive Oxygen Species , Time Factors , bcl-X Protein
SELECTION OF CITATIONS
SEARCH DETAIL
...